LakeShore Biopharma Income Statement

Financials in millions CNY. Fiscal year is April - March.

Millions CNY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	573.42	687.2	502.95	257.02
Revenue Growth (YoY)	-16.56%	36.63%	95.69%	-
Cost of Revenue	187.36	153.36	121.46	59.66
Gross Profit	386.06	533.84	381.49	197.36
Selling, General & Admin	434.56	339.33	278.76	224.82
Research & Development	302.8	318.7	211.22	94.39
Other Operating Expenses	6.79	6.54	5.38	4
Operating Expenses	744.15	664.57	495.37	323.21
Operating Income	-358.09	-130.73	-113.88	-125.85
Interest Expense	-44.34	-30.86	-2.72	-29.69
Other Non Operating Income (Expenses)	27.48	17.24	15.53	-18.83
EBT Excluding Unusual Items	-374.96	-144.35	-101.07	-174.37
Gain (Loss) on Sale of Investments	-	-137.99	-130.66	-16.61
Asset Writedown	-80.24	-	-	-
Pretax Income	-455.19	-282.34	-231.73	-190.98
Income Tax Expense	-21.73	1.13	4.94	17.45
Net Income	-433.46	-283.47	-236.67	-208.44
Preferred Dividends & Other Adjustments	-	-137.99	-130.66	-16.61
Net Income to Common	-433.46	-145.48	-106	-191.83
Shares Outstanding (Basic)	11	6	6	6
Shares Outstanding (Diluted)	11	6	6	6
Shares Change (YoY)	73.06%	-0.07%	-	-
EPS (Basic)	-40.54	-23.55	-17.15	-31.03
EPS (Diluted)	-40.54	-23.55	-17.15	-31.03
Free Cash Flow	-339.48	-235.23	-468.86	-351.49
Free Cash Flow Per Share	-31.75	-38.07	-75.83	-56.85
Gross Margin	67.33%	77.68%	75.85%	76.79%
Operating Margin	-62.45%	-19.02%	-22.64%	-48.96%
Profit Margin	-75.59%	-21.17%	-21.08%	-74.64%
Free Cash Flow Margin	-59.20%	-34.23%	-93.22%	-136.76%
EBITDA	-315.9	-94.04	-82.72	-97.94
EBITDA Margin	-55.09%	-13.68%	-16.45%	-38.11%
D&A For EBITDA	42.19	36.69	31.15	27.91
EBIT	-358.09	-130.73	-113.88	-125.85
EBIT Margin	-62.45%	-19.02%	-22.64%	-48.96%

Updated Aug 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q